Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Income from Continuing Operations (2024 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Income from Continuing Operations for 4 consecutive years, with 12187000.0 as the latest value for Q3 2025.

  • Quarterly Income from Continuing Operations rose 80.87% to 12187000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 127498000.0 through Sep 2025, up 28.77% year-over-year, with the annual reading at 116215000.0 for FY2011, 14.19% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 12187000.0 at Lexicon Pharmaceuticals, down from 3736000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 3736000.0 in Q2 2025, with the low at 63693000.0 in Q3 2024.